(Q53910434)

22 May 2018

title

Open label trial of oral clarithromycin in active Crohn's disease. (English)

1 reference

22 May 2018

1 reference

1 reference

Leiper K

1

1 reference

22 May 2018

Morris AI

series ordinal

2

1 reference

22 May 2018

Rhodes JM

series ordinal

3

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 June 2000

1 reference

22 May 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

22 May 2018

volume

14

1 reference

22 May 2018

issue

6

1 reference

22 May 2018

page(s)

801-806

1 reference

22 May 2018

The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Double blind, placebo controlled trial of metronidazole in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Controlled trial of rifampicin and ethambutol in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Effect of macrolide antibiotics on macrophage functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Mycobacterium paratuberculosis DNA in Crohn's disease tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Leucocyte function in Crohn's disease. Studies on mobilisation using a quantitative skin window technique and on the function of circulating polymorphonuclear leucocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Neutrophil dysfunction in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00753.X

10.1046/J.1365-2036.2000.00753.X

21 January 2018

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018